Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic
Authors:
- Li-Li XuLXLi-Li Xu
- Feng-Di LiFLFeng-Di Li
- Lin-Lin BaoLBLin-Lin Bao
- Chuan QinCQChuan Qin
- Zhan-Cheng GaoZGZhan-Cheng Gao
- 1 December 2011
- journal article
- Published by Elsevier in Medical Hypotheses
- Vol. 77 (6) , 1054-1057
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology of China (2009ZX10004-016)
This publication has 34 references indexed in Scilit:
- Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus InfectionNew England Journal of Medicine, 2010
- Insights into Inflammation and InfluenzaNew England Journal of Medicine, 2008
- Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune responseImmunological Reviews, 2008
- Update on Avian Influenza A (H5N1) Virus Infection in HumansNew England Journal of Medicine, 2008
- Treatment with Convalescent Plasma for Influenza A (H5N1) InfectionNew England Journal of Medicine, 2007
- Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemiaNature Medicine, 2006
- Oseltamivir Resistance during Treatment of Influenza A (H5N1) InfectionNew England Journal of Medicine, 2005
- Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cellsRespiratory Research, 2005
- Cutting Edge: HMG-1 as a Mediator of Acute Lung InflammationThe Journal of Immunology, 2000
- HMG-1 as a Late Mediator of Endotoxin Lethality in MiceScience, 1999